Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits
about
Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspironeA delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learningPharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysisOld dog, new tricks: the attentional set-shifting test as a novel cognitive behavioral task after controlled cortical impact injury.Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesisAggression, DRD1 polymorphism, and lesion location in penetrating traumatic brain injury.Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.Abbreviated environmental enrichment enhances neurobehavioral recovery comparably to continuous exposure after traumatic brain injury.Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats.Addressing neuropsychiatric disturbances during rehabilitation after traumatic brain injury: current and future methods.Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficitsTargeting Dopamine in Acute Traumatic Brain InjuryPsychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury.Traumatic Brain Injury Patient, Injury, Therapy, and Ancillary Treatments Associated With Outcomes at Discharge and 9 Months PostdischargeCatecholaminergic based therapies for functional recovery after TBIAdministration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact.Impact of pharmacological treatments on outcome in adult rodents after traumatic brain injury: a meta-analysis.Emergency neurological life support: airway, ventilation, and sedation.Blood-brain barrier dysfunction following traumatic brain injury.5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.Comparable impediment of cognitive function in female and male rats subsequent to daily administration of haloperidol after traumatic brain injury.Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice.GSNO promotes functional recovery in experimental TBI by stabilizing HIF-1α.Intermittent treatment with haloperidol or quetiapine does not disrupt motor and cognitive recovery after experimental brain trauma.Combining the Antipsychotic Drug Haloperidol and Environmental Enrichment after Traumatic Brain Injury Is a Double-Edged Sword.FeTPPS Reduces Secondary Damage and Improves Neurobehavioral Functions after Traumatic Brain Injury.BPSD following traumatic brain injury.Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam.Refining environmental enrichment to advance rehabilitation based research after experimental traumatic brain injury.Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
P2860
Q24633449-385319B7-03A0-4E14-B84C-C069ABC22D25Q24651403-FEFDA25B-415F-4A28-9037-BD905C3A46F2Q28821103-8C27A49B-F7D1-4C81-B4DA-EEB78E4C298AQ33576385-EC2450B8-FD56-4CE2-BB21-9D210DFB9E42Q33589580-0D33E5FC-0944-4BDB-AD90-85F080A9C414Q34167783-B3D9222A-5AC1-4D5F-9707-1C35F129DBCEQ34296853-453EA088-58CF-499B-A107-41A582BA7C90Q34749970-5292E4AC-9823-4C0A-9742-AAB6DFE59787Q35136513-77D042C6-09B5-42FB-AC20-7A58C1884C20Q35172025-D5F198BE-F068-4FBB-A87C-1E0C4357E065Q35237359-925848B3-764E-496A-B8B0-02A6A899B2D7Q35376749-D47CCC2B-F705-4EAF-A6F0-3EA7FA7667CBQ35720254-355302D9-256C-4351-A312-48F7470FE132Q35894647-28E94051-EA33-4474-A8AA-CEB57BACEAC5Q35895824-7DCD093E-E418-4225-AC34-91015903253BQ36909436-B14CA5A4-38E2-4210-8AF1-E1C28840696EQ37420533-F137560A-C054-48BA-9203-FC5866388876Q37837257-46D5B33C-07E5-44FF-884E-4F9669050AE6Q38042830-258EC956-C1CD-4E12-8313-EDE68065E627Q38333690-7F3CD03D-0FD9-41C8-AC34-B9430119DA32Q38650071-BB90F4A5-504C-4B07-B839-DC435B9B512EQ38683606-72035475-36D1-4279-BBA2-060FFD402207Q38747752-2ACFF550-74C8-415B-885E-70C915471CCDQ39202524-55D2AC18-1630-40F3-80B0-37D11630F5B8Q39250264-997A9E59-95B4-47D6-B7B6-02D268AECC63Q39355321-AE6FEF3B-0B6F-42BF-91F8-DEE4F3334BF7Q39921323-F06C8A3D-0AFB-4A28-9D29-467ED993E5CCQ41852720-BBC48D49-BFD3-4075-80C5-B6053202718CQ47134834-F8A8F6E5-856A-42D7-9B08-A9A3B991E9C2Q47371361-754B85C9-9E1A-4A72-9C81-3B68C131C324Q47891032-0897E3B3-2927-4283-AB5E-7715E879596EQ48713412-6DFB1159-CED7-4886-8F25-CD432B2B8BD0Q58739852-0205FA6A-AA71-4ED6-B56B-019F89AB4CFF
P2860
Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Administration of haloperidol ...... brain injury-induced deficits
@en
Administration of haloperidol ...... brain injury-induced deficits.
@nl
type
label
Administration of haloperidol ...... brain injury-induced deficits
@en
Administration of haloperidol ...... brain injury-induced deficits.
@nl
prefLabel
Administration of haloperidol ...... brain injury-induced deficits
@en
Administration of haloperidol ...... brain injury-induced deficits.
@nl
P2093
P2860
P1433
P1476
Administration of haloperidol ...... brain injury-induced deficits
@en
P2093
Ann N Hoffman
Anthony E Kline
Ross D Zafonte
P2860
P304
P356
10.1016/J.LFS.2008.08.007
P407
P577
2008-08-31T00:00:00Z